Clinical Development of TargomiRs, a miRNA Mimic-Based Treatment for Patients with Recurrent Thoracic Cancer

References

• Garzon R , CalinGA , CroceCM . MicroRNAs in cancer . Annu. Rev. Med.60167 – 179 ( 2009 ).
   PubMed Web of Science ®Google Scholar
• Bichi R , ShintonSA , MartinESet al. Human chronic lymphocytic leukemia modeled in mouse by targeted TCL1 expression . Proc. Natl Acad. Sci. USA99 ( 10 ), 6955 – 6960 ( 2002 ).
   PubMed Web of Science ®Google Scholar
• Lee YS , DuttaA . MicroRNAs in cancer . Annu. Rev. Pathol.4 , 199 – 227 ( 2009 ).
   PubMed Web of Science ®Google Scholar
• Kasinski AL , SlackFJ . Epigenetics and genetics. MicroRNAs en route to the clinic: progress in validating and targeting microRNAs for cancer therapy . Nat. Rev. Cancer11 ( 12 ), 849 – 864 ( 2011 ).
   PubMed Web of Science ®Google Scholar
• Hanahan D , WeinbergRA . Hallmarks of cancer: the next generation . Cell144 ( 5 ), 646 – 674 ( 2011 ).
   PubMed Web of Science ®Google Scholar
• Lu J , GetzG , MiskaEAet al. MicroRNA expression profiles classify human cancers . Nature435 ( 7043 ), 834 – 838 ( 2005 ).
   PubMed Web of Science ®Google Scholar
• Henry JC , Azevedo-PoulyAC , SchmittgenTD . MicroRNA replacement therapy for cancer . Pharm. Res.28 ( 12 ), 3030 – 3042 ( 2011 ).
   PubMed Web of Science ®Google Scholar
• Akao Y , NakagawaY , HirataIet al. Role of anti-oncomirs miR-143 and -145 in human colorectal tumors . Cancer Gene Ther.17 ( 6 ), 398 – 408 ( 2010 ).
   PubMed Web of Science ®Google Scholar
• Ibrahim AF , WeirauchU , ThomasM , GrunwellerA , HartmannRK , AignerA . MicroRNA replacement therapy for miR-145 and miR-33a is efficacious in a model of colon carcinoma . Cancer Res.71 ( 15 ), 5214 – 5224 ( 2011 ).
   PubMed Web of Science ®Google Scholar
• Reid G , PelME , KirschnerMBet al. Restoring expression of miR-16: a novel approach to therapy for malignant pleural mesothelioma . Ann. Oncol.24 ( 12 ), 3128 – 3135 ( 2013 ).
   PubMed Web of Science ®Google Scholar
• Takeshita F , PatrawalaL , OsakiMet al. Systemic delivery of synthetic microRNA-16 inhibits the growth of metastatic prostate tumors via downregulation of multiple cell-cycle genes . Mol. Ther.18 ( 1 ), 181 – 187 ( 2010 ).
   PubMed Web of Science ®Google Scholar
• Trang P , MedinaPP , WigginsJFet al. Regression of murine lung tumors by the let-7 microRNA . Oncogene29 ( 11 ), 1580 – 1587 ( 2010 ).
   PubMed Web of Science ®Google Scholar
• Wiggins JF , RuffinoL , KelnarKet al. Development of a lung cancer therapeutic based on the tumor suppressor microRNA-34 . Cancer Res.70 ( 14 ), 5923 – 5930 ( 2010 ).
   PubMed Web of Science ®Google Scholar
• Zhao J , KelnarK , BaderAG . In-depth analysis shows synergy between erlotinib and miR-34a . PLoS ONE9 ( 2 ), e89105 ( 2014 ).
   PubMed Web of Science ®Google Scholar
• Fortunato O , BoeriM , VerriC , MoroM , SozziG . Therapeutic use of microRNAs in lung cancer . Biomed. Res. Int.2014 , 756975 ( 2014 ).
   PubMed Web of Science ®Google Scholar
• Johnson SM , GrosshansH , ShingaraJet al. RAS is regulated by the let-7 microRNA family . Cell120 ( 5 ), 635 – 647 ( 2005 ).
   PubMed Web of Science ®Google Scholar
• Johnson CD , Esquela-KerscherA , StefaniGet al. The let-7 microRNA represses cell proliferation pathways in human cells . Cancer Res.67 ( 16 ), 7713 – 7722 ( 2007 ).
   PubMed Web of Science ®Google Scholar
• Esquela-Kerscher A , TrangP , WigginsJFet al. The let-7 microRNA reduces tumor growth in mouse models of lung cancer . Cell Cycle7 ( 6 ), 759 – 764 ( 2008 ).
   PubMed Web of Science ®Google Scholar
• Bader AG . miR-34 – a microRNA replacement therapy is headed to the clinic . Front. Genet.3 , 120 ( 2012 ).
   PubMedGoogle Scholar
• Trang P , WigginsJF , DaigeCLet al. Systemic delivery of tumor suppressor microRNA mimics using a neutral lipid emulsion inhibits lung tumors in mice . Mol. Ther.19 ( 6 ), 1116 – 1122 ( 2011 ).
   PubMed Web of Science ®Google Scholar
• Wu Y , CrawfordM , MaoYet al. Therapeutic delivery of microRNA-29b by cationic lipoplexes for lung cancer . Mol. Ther. Nucleic Acids2e84 ( 2013 ).
   PubMedGoogle Scholar
• Cortez MA , ValdecanasD , ZhangXet al. Therapeutic delivery of miR-200c enhances radiosensitivity in lung cancer . Mol. Ther.22 ( 8 ), 1494 – 1503 ( 2014 ).
   PubMed Web of Science ®Google Scholar
• Kasinski AL , KelnarK , StahlhutCet al. A combinatorial microRNA therapeutics approach to suppressing non-small cell lung cancer . Oncogene34 ( 27 ), 3547 – 3555 ( 2015 ).
   PubMed Web of Science ®Google Scholar
• Birnie KA , YipYY , NgDCet al. Loss of miR-223 and JNK signaling contribute to elevated stathmin in malignant pleural mesothelioma . Mol. Cancer Res.13 ( 7 ), 1106 – 1118 ( 2015 ).
   PubMed Web of Science ®Google Scholar
• Kirschner MB , ChengYY , BadrianBet al. Increased circulating miR-625-3p: a potential biomarker for patients with malignant pleural mesothelioma . J. Thorac. Oncol.7 ( 7 ), 1184 – 1191 ( 2012 ).
   PubMed Web of Science ®Google Scholar
• Bonci D , CoppolaV , MusumeciMet al. The miR-15a–miR-16-1 cluster controls prostate cancer by targeting multiple oncogenic activities . Nat. Med.14 ( 11 ), 1271 – 1277 ( 2008 ).
   PubMed Web of Science ®Google Scholar
• Bandi N , ZbindenS , GuggerMet al. miR-15a and miR-16 are implicated in cell cycle regulation in a Rb-dependent manner and are frequently deleted or down-regulated in non-small cell lung cancer . Cancer Res.69 ( 13 ), 5553 – 5559 ( 2009 ).
   PubMed Web of Science ®Google Scholar
• Cimmino A , CalinGA , FabbriMet al. miR-15 and miR-16 induce apoptosis by targeting BCL2 . Proc. Natl Acad. Sci. USA102 ( 39 ), 13944 – 13949 ( 2005 ).
   PubMed Web of Science ®Google Scholar
• Williams M , KirschnerMB , ChengYYet al. miR-193a-3p is a potential tumor suppressor in malignant pleural mesothelioma . Oncotarget6 ( 27 ), 23480 – 23495 ( 2015 ).
   PubMedGoogle Scholar
• Ueno T , ToyookaS , FukazawaTet al. Preclinical evaluation of microRNA-34b/c delivery for malignant pleural mesothelioma . Acta Med. Okayama68 ( 1 ), 23 – 26 ( 2014 ).
   PubMed Web of Science ®Google Scholar
• Finnerty JR , WangWX , HebertSS , WilfredBR , MaoG , NelsonPT . The miR-15/107 group of microRNA genes: evolutionary biology, cellular functions, and roles in human diseases . J. Mol. Biol.402 ( 3 ), 491 – 509 ( 2010 ).
   PubMed Web of Science ®Google Scholar
• Reid GWM , KirschnerMb , MugridgeNet al. Targeted delivery of a synthetic microRNA-based mimic as an approach to cancer therapy . Cancer Res.75 ( Suppl. 15 ), Abstract 3976 ( 2015 ).
   Google Scholar
• MacDiarmid JA , MugridgeNB , WeissJCet al. Bacterially derived 400 nm particles for encapsulation and cancer cell targeting of chemotherapeutics . Cancer Cell11 ( 5 ), 431 – 445 ( 2007 ).
   PubMed Web of Science ®Google Scholar
• MacDiarmid JA , Amaro-MugridgeNB , Madrid-WeissJet al. Sequential treatment of drug-resistant tumors with targeted minicells containing siRNA or a cytotoxic drug . Nat. Biotechnol.27 ( 7 ), 643 – 651 ( 2009 ).
   PubMed Web of Science ®Google Scholar
• Glover AR , ZhaoJT , GillAJet al. microRNA-7 as a tumor suppressor and novel therapeutic for adrenocortical carcinoma . Oncotarget6 ( 34 ), 36675 – 36688 ( 2015 ).
   PubMedGoogle Scholar
• Beg MS , BrennerA , SachdevJet al. Safety, tolerability, and clinical activity of MRX34, the first-in-class liposomal miR-34 mimic, in patients with advanced solid tumors . Presented at : AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics.Boston, MA, USA , 5–9 November2015 .
   Google Scholar
• Solomon BJ , DesaiJ , RosenthalMet al. A first-time-in-human Phase I clinical trial of bispecific antibody-targeted, paclitaxel-packaged bacterial minicells . PLoS ONE10 ( 12 ), e0144559 ( 2015 ).
   PubMed Web of Science ®Google Scholar
• Whittle JR , LickliterJD , GanHKet al. First in human nanotechnology doxorubicin delivery system to target epidermal growth factor receptors in recurrent glioblastoma . J. Clin. Neurosci.22 ( 12 ), 1889 – 1894 ( 2015 ).
   PubMed Web of Science ®Google Scholar
• Kao SC , FulhamM , WongKet al. A significant metabolic and radiological response after a novel targeted microRNA-based treatment approach in malignant pleural mesothelioma . Am. J. Respir. Crit. Care Med.191 ( 12 ), 1467 – 1469 ( 2015 ).
   PubMed Web of Science ®Google Scholar
• Bernardo BC , GaoXM , ThamYKet al. Silencing of miR-34a attenuates cardiac dysfunction in a setting of moderate, but not severe, hypertrophic cardiomyopathy . PLoS ONE9 ( 2 ), e90337 ( 2014 ).
   PubMed Web of Science ®Google Scholar
• Bernardo BC , GaoXM , WinbanksCEet al. Therapeutic inhibition of the miR-34 family attenuates pathological cardiac remodeling and improves heart function . Proc. Natl Acad. Sci. USA109 ( 43 ), 17615 – 17620 ( 2012 ).
   PubMed Web of Science ®Google Scholar
• Alley EW ML , SantoroA , BeckeyKet al. Clinical safety and efficacy of pembrolizumab (MK-3475) in patients with malignant pleural mesothelioma: preliminary results from KEYNOTE-028 . Cancer Res.75 ( Suppl. 15 ), Abstract CT103 ( 2015 ).
   Google Scholar
• Borghaei H , Paz-AresL , HornLet al. Nivolumab versus docetaxel in advanced nonsquamous non-small-cell lung cancer . N. Engl. J. Med.373 ( 17 ), 1627 – 1639 ( 2015 ).
   PubMed Web of Science ®Google Scholar
• Brahmer J , ReckampKL , BaasPet al. Nivolumab versus docetaxel in advanced squamous-cell non-small-cell lung cancer . N. Engl. J. Med.373 ( 2 ), 123 – 135 ( 2015 ).
   PubMed Web of Science ®Google Scholar
• Cortez MA , IvanC , ValdecanasDet al. PDL1 regulation by p53 via miR-34 . J. Natl Cancer Inst.108 ( 1 ), djv303 ( 2016 ).
   PubMedGoogle Scholar